Recent antimalarial drug discovery has been a race to produce new medicines that
overcome emerging drug resistance, whilst considering safety and improving dosing …

Malaria remains one of the most important infectious diseases in the world, with the greatest
burden in sub-Saharan Africa, primarily from Plasmodium falciparum infection. The …

The global adoption of artemisinin-based combination therapies (ACTs) in the early 2000s
heralded a new era in effectively treating drug-resistant Plasmodium falciparum malaria …

Malaria is among the most devastating and widespread tropical parasitic diseases in which
most prevalent in develo** countries. Antimalarial drug resistance is the ability of a …

The emergence of mutant K13-mediated artemisinin (ART) resistance in Plasmodium
falciparum malaria parasites has led to widespread treatment failures across Southeast …

Infectious tropical diseases have a huge effect in terms of mortality and morbidity, and
impose a heavy economic burden on affected countries. These diseases predominantly …

Chemogenetic characterization through in vitro evolution combined with whole-genome
analysis can identify antimalarial drug targets and drug-resistance genes. We performed a …

The Malaria Drug Accelerator (MalDA) is a consortium of 15 leading scientific laboratories.
The aim of MalDA is to improve and accelerate the early antimalarial drug discovery process …

Drug resistance is an obstacle to global malaria control, as evidenced by the recent
emergence and rapid spread of delayed artemisinin (ART) clearance by mutant forms of the …

Human to vector transmission of malaria requires that some blood-stage parasites abandon
asexual growth and convert into non-replicating sexual forms called gametocytes. The initial …